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Abstract
Background: Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a
median survival of 15 months. The standard treatment for these lesions includes maximal resection, radiotherapy,
and chemotherapy; however, individual tumors display immense variability in their response to these approaches.
Genomic techniques such as whole-exome sequencing (WES) provide an opportunity to understand the molecular
basis of this variability.
Methods: Here, we report WES-guided treatment of a patient with a primary GBM and two subsequent recurrences,
demonstrating the dynamic nature of treatment-induced molecular changes and their implications for clinical
decision-making. We also analyze the Yale-Glioma cohort, composed of 110 whole exome- or whole genome-
sequenced tumor-normal pairs, to assess the frequency of genomic events found in the presented case.
Results: Our longitudinal analysis revealed how the genomic profile evolved under the pressure of therapy.
Specifically targeted approaches eradicated treatment-sensitive clones while enriching for resistant ones,
generated due to chromothripsis, which we show to be a frequent event in GBMs based on our extended
analysis of 110 gliomas in the Yale-Glioma cohort. Despite chromothripsis and the later acquired mismatch-repair
deficiency, genomics-guided personalized treatment extended survival to over 5 years. Interestingly, the
case displayed a favorable response to immune checkpoint inhibition after acquiring mismatch repair
deficiency.
Conclusions: Our study demonstrates the importance of longitudinal genomic profiling to adjust to the
dynamic nature of treatment-induced molecular changes to improve the outcomes of precision therapies.
Keywords: Genomics-guided precision medicine, Tumor evolution, Longitudinal genomic analysis, Immune
checkpoint inhibition, Mismatch repair deficiency, Glioma
Background
Glioblastoma multiforme (GBM) constitutes 15.6% of
all and 45.2% of malignant brain tumors, with a poor
prognosis and 5-year survival in less than 5% of cases.
Besides the heterogeneity among different histologies
and grades, glial tumors also show significant inter- and
intra-tumor heterogeneity [1, 2], a feature that carries
important implications for both targeted and standard-
of-care treatments. Here, we present longitudinal
whole-exome sequencing (WES) of a GBM patient
undergoing treatment and report rapid evolution in re-
sponse to targeted clinical approaches. Our longitudinal
analysis spanned 5 years and revealed how the genomic
profile evolved under the pressure of targeted therapy,
specifically leading to the eradication of treatment-
sensitive clones while enriching for those that showed
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resistance. The results of this analysis helped to guide
personalized, precise treatment of the patient despite
having two therapeutically adverse events with two re-
currences, chromothripsis and mismatch repair (MMR)
deficiency. The patient initially had chromothripsis, creat-
ing double minutes (DMs) resistant to targeted therapies.
To assess the frequency of chromothripsis in GBMs and
to emphasize its impact on clinical decisions, we further
analyzed the Yale-Glioma cohort composed of 110 whole
exome- or whole genome-sequenced tumor-normal pairs.
The presented case later acquired MMR deficiency with
the second recurrence, leading to resistance to alkylat-
ing agent treatments and a hypermutated phenotype.
Interestingly, the case displayed a favorable response to
immune checkpoint inhibition after acquiring mis-
match repair deficiency. With this clinical approach,
the patient survived more than 5 years despite the two
recurrences (Fig. 1). Our study exemplifies how gen-
omic profiling can successfully guide personalized treat-
ment regimens, even in aggressive cancers such as
GBM. Our observations also emphasize the necessity of
genomic profiling and comparative analyses for each
clinical recurrence or progression.
Methods
Ethics and consent of clinical materials
Institutional review board approvals for genetic studies,
along with written consent from all study subjects, were
obtained at the participating institutions.
Exome capture and sequencing
Exome capture was performed with a Nimblegen/Roche
human solution-capture exome array (Roche Nimblegen,
Inc.) [3]. Sequencing of the library was performed on Illu-
mina HiSeq machines (Additional file 1). For molecular
profiling of the tumors, we performed deep WES of the
primary GBM tumor, first recurrence, and second recur-
rence, together with the matching normal blood. We
achieved high mean target coverage of 209.5×, 229.4×,
199.6×, and 92.6×, respectively. We analyzed all
three exome sequencing data sets to detect somatic
single-nucleotide variations (SNVs), insertion/dele-
tions (INDELs), copy number variations (CNVs),
and structural variations (SVs). We also performed
comparative analyses among all three samples to
understand the temporal evolution of the tumor
under the pressure of not only standard-of-care but
also targeted therapies.
For the Yale-Glioma cohort, we achieved mean target
coverage of 194.3 and 121.3, for tumors and matching
blood, respectively. The average percentage of reads with
at least 20× coverage was 91.0 and 88.4% for tumor and
blood, respectively.
Exome sequencing data analysis: somatic SNV/INDEL and
CNV analysis
We performed quality control, alignment, PCR duplicate
marking, multi-sequence local realignment, base quality
score recalibration, and calling of somatic SNV/INDELS
Fig. 1 Clinical progression of the presented case. Treatments are represented with colored bars: temozolomide treatment in pink; vandetanib
(targeted EGFR treatment) in purple, carboxyamidotriazole orotate (CTO; targeted phosphoinositide 3-kinase treatment) in yellow, immunotherapy
in dark blue, hydroxurea in red, radiation in light blue, and bevacizumab in magenta
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(using Haplotyper in Genome Analysis Toolkit, version
2.5) as described previously in [4]. We calculated the
clonality rate of mutations based on the variant allele
frequency, ploidy at the site, and the admixture rate [5].
We performed the CNV analysis on all tumors using the
ExomeCNV package [6]. We used Breakdancer [7] to
call breakpoints, applied filtering on the raw calls,
and performed annotation using ANNOVAR (Additional
file 1).
We used the Mclust package in R (http://www.stat.wa-
shington.edu/mclust/) to cluster the unique somatic mu-
tations (coding region and captured non-coding regions)
in three tumors based on their clonality rate distribu-
tions. Bayesian Information Criteria (BIC) was used to
find the model with the optimal number of clusters. The
analysis identified clusters, which we used to depict the
tumor evolution.
Whole-genome capture and sequencing
Whole-genome sequencing was performed by Complete
Genomics Cancer Sequencing Service v2.0 and down-
stream analysis was performed with in-house scripts
(Additional file 1).
Tumor cells in culture
Short-term cultured tumor cells were harvested using
trypsin, pelleted by centrifugation, re-suspended in a
small volume of phosphate-buffered saline (PBS), and in-
cubated for 20 min in a large volume (10–15 ml) of
hypotonic 75 mM KCl at 37 °C to increase cell volume
and facilitate cell membrane rupture. One volume of 3:1
methanol:acetic acid was slowly added to the cell sus-
pension and cells were pelleted by centrifugation for
5 min at 1200 rpm/400 g. The cell/nuclear pellet was
resuspended in 5 ml fresh 3:1 fixative, incubated for 10–
15 min at room temperature (RT), and centrifuged again
as before. This step was repeated two more times. After
the final centrifugation step, the cell pellet was trans-
ferred for storage into a 1.5 ml microfuge tube in a small
volume of fixative. Unused cells were stored indefinitely
in fixative at −20 °C. Prior to spreading on clean slides,
cells were resuspended in fresh 3:1 fixative. To obtain
cytogenetic preparations/slides with nuclei as flat as
possible, the procedure was modified as described in
detail elsewhere [8]. Slides were always prepared
fresh; only cell pellets were stored long term. After
preparation, for fast fixation/dehydration, slides were
covered with a long coverslip, ethanol was added to
form a thin layer between the slide and the coverslip,
and slides were incubated for 1–2 min at 85–90 °C
on a heat block, while adding fresh ethanol every few
seconds with a pipette in order to prevent complete etha-
nol evaporation. Afterwards, for tissue “permeabilization”,
the dry slides were incubated for 1.5–2 min in a jar
with 0.005% pepsin/0.01 M HCl at 37 °C, followed by
brief (1–2 min each) rinsing in PBS, 70% ethanol, and
100% ethanol and RT drying. To decrease background
signals during FISH, slides were incubated for 10 min
with a 0.1 mg/ml solution of RNAse A in PBS,
followed by rinsing in PBS, 70 and 100% ethanol
(2 min each), and air-dried.
DNA FISH probe preparation and labeling
We used the following BACs: BAC RPCI-11 433 N15
(for MDM4) and BACs RPCI-11 1112G8, and 148P17
(for EGFR). BAC-containing live bacteria were commer-
cially obtained (Invitrogen). DNA was prepared via
mini-preps using the standard procedure (Qiagen mini-
prep kit). BAC DNA was labeled by nick translation. A
20-μl reaction included: 500 ng BAC DNA, 2 μl 10×
Escherichia coli buffer, 2 μl 10× DNAseI solution; 1 μl
d(ACG), 1 mM each; 0.1 μl dTTP, 5 mM; 0.25 μl DIG-
dUTP or BIO-dUTP, 1 mM; 0.5 μl E. coli Pol I (10 U/μl;
New England Biolabs); and water (to 20 μl). Incubation
was for 2 h at 15 °C followed by purification either by
ethanol precipitation or using the Qiagen PCR purifica-
tion kit. The 10× DNAse solution was prepared with
1 μl 1 mg/ml DNaseI (Sigma) + 1 ml water and was al-
ways made fresh before use. After purification, the la-
beled DNA probe was resuspended in 10–20 μl FISH
buffer (50% formamide, 2× SSC, 10% dextran sulfate, 1×
phosphate buffer = 50 mM 5:1 sodium phosphate diba-
sic:mono basic, pH 7.0). Cot1 DNA (Invitrogen) was
also ethanol precipitated and resuspended at 10 μg/μl
in FISH buffer. Prior to FISH experiments, we mixed
4 μl FISH probe with 2–3 μl CotI DNA, placed 6–7 μl
per slide, which was covered with a small 12 × 12 mm
coverslip and the slide and probe denatured for 3 min
at 80–85 °C.
DNA hybridization and detection
For FISH using simultaneous slide and probe denatur-
ing, 5–6 μl FISH probe was pipetted on the slide,
covered with a 12x12mm coverslip, sealed with rub-
ber cement, and both the slide and probe heat-
denatured for 3–3.5 min at 80 °C on a heat block,
followed by 24-h incubation at 37 °C in a water bath
or incubator.
After hybridization, coverslips were removed from the
slides with fine forceps. Slides were incubated for
15 min in a jar with 2° SSC at 37 °C, followed by a
15 min incubation in 2× SSC at RT. After a brief rinse
in a jar with distilled water, slides were transferred to a
jar with 1× PBS. To pre-block the slide, we added 50–
100 μl BSDSGS/0.1% Tween (10× BSDSGS contains PBS
with 1% bovine serum albumin, 5% donkey serum, 5%
goat serum, 0.1% glycine, 0.1% lysine). The primary anti-
body (mouse-anti-DIG, Sigma) was diluted 1:100 in
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BSDSGS and 100 μl added to the slide. For BIO-dUTP-
labeled probes, at this step we also added Avidin-FITC
(or Streptavidin-Alexa 488), 1:100 diluted in BSDSGS/
0.1% Tween20. This was followed by a 2 h incubation
at 37 °C, though RT incubation works equally well.
After a 15-min rinse in PBS, 100 μl of a secondary
antibody (usually donkey-anti-mouse-Alexa555, Invi-
trogen) diluted at 1:500 in BSDSGS/0.1% Tween was
placed on the slide and incubated for 15–30 min at
RT followed by a 15-min 1× PBS wash. After a brief
rinse in distilled water to remove excess salt, the
slide was air-dried, mounted with DAPI-antifade
(Vector Laboratories), covered with a coverslip, and
examined with a microscope (Zeiss Axiophot) using
appropriate fluorescence filters. Images were captured
with Zeiss software and colored images merged in
Photoshop (Adobe).
Results
The patient was a 55-year-old right-handed woman who
presented to medical attention in June 2010 after sud-
denly developing expressive aphasia and confusion. Her
initial brain MRI revealed a heterogeneously enhancing
infiltrating tumor, and she underwent surgical resection
in July 2010. WES analysis of this tumor and matching
blood revealed amplification of chromosome 7 and dele-
tion of chromosome 10, together with focal deletion of
the cyclin-dependent kinase inhibitor 2A (CDKN2A)
locus on chromosome 9. Detailed analysis of the CNVs
and SVs revealed segments on chromosomes 7p.11 and
1q.32, with more than 20 copies overlapping with the
EGFR and Mdm2-like P53-binding protein (MDM4)
genes, respectively (Fig. 2a). Interestingly, regions with
high copy numbers also showed an increased number of
intra-chromosomal breaks that were supported by high
numbers of reads (>100) on WES (Fig. 2a). Taken to-
gether, these findings suggested that the tumor cells had
undergone chromothripsis [9]. Chromothripsis, shatter-
ing, and reassembling of chromosomes leading to ampli-
fication and deletion of segments through end joining-
based repair or by DM chromosome formation [10] has
been observed in 2–3% of cancers [11, 12], including
pediatric neuroblastoma [13] and medulloblastoma [14],
colorectal cancer, breast cancer [15], melanoma [16], as
well as glioma [17].
In addition to high ploidy of EGFR in the primary
tumor, we also identified an activating ectodomain EGFR
A289V mutation, which has been previously shown to
lead to oncogenic activation [18] and harbor sensitivity
to kinase inhibitors, such as lapatinib [19]. The patient
was started on standard chemotherapy and radiation
with temozolomide and was enrolled in a clinical trial
for the receptor tyrosine kinase inhibitor, vandetanib.
She completed 12 cycles of adjuvant temozolomide and
vandetanib in October 2011 and continued vandetanib
alone until disease progression was noted on MRI in
February 2013. She underwent a second gross total resec-
tion in March, and WES of this recurrent tumor revealed
a similar profile to the primary tumor with amplification
of chromosome 7 and deletions of chromosome 10 and
the CDKN2A locus on chromosome 9. Interestingly, when
we compared the genomic profiles of the primary tumor
and the first recurrence, we observed loss of the tumor
cells harboring the activating EGFR A289V mutation,
most likely due to the targeted anti-EGFR therapy with
vandetanib, but preservation of EGFR amplification
(Fig. 2b). This observation suggested that even though the
anti-EGFR therapy resulted in the eradication of the
tumor sub-clone with the activating EGFR A289V muta-
tion, it had no impact on the high EGFR ploidy. Given
these molecular profiling results, which again re-
vealed deletion of the PTEN locus, the patient was
started on a clinical trial with carboxyamidotriazole
orotate (CTO) to target the activated phosphoinosi-
tide 3-kinase (PI3K) pathway along with concomitant
temozolomide treatment (March 2013). A brain MRI
performed 4 months after resection revealed a 4-mm
nodular contrast enhancement at the posterior mar-
gin of the resection cavity. Of note, this nodule got
smaller in subsequent scans (data not shown).
During the combination therapy of CTO and temozo-
lomide, a second recurrence, diagnosed based on both
clinical and radiographic evidence, occurred in June
2014. At that time, the patient developed worsening
speech and a new area of nodular contrast enhancement
along the posterior and inferior margins of the resection
cavity. Based on these findings, she underwent a third
resection in June 2014. WES of this second tumor re-
currence again showed chromosome 10 and CDKN2A
deletion but even more interestingly still high ploidy
of the EGFR/MDM4 loci (>10 and >6, respectively).
Given this observation, we tested whether the persist-
ing high EGFR ploidy was due to the formation of
DMs or homogeneously staining regions, which are
extra-chromosomal and intra-chromosomal amplifica-
tions of segments, respectively. Indeed, EGFR and
MDM4 FISH analysis of the patient-derived primary
GBM cells from the second recurrence showed the
presence of DMs, which are known to be resistant to
targeted chemotherapies as previously reported (Fig. 3)
[20, 21].
After demonstrating chromothripsis affecting also the
second recurrence, we focused on the somatic mutation
count of the second recurrence tumor. This tumor har-
bored a hypermutated phenotype (2079 somatic coding
mutations versus 68 and 70 in the primary and first re-
currence tumors, respectively). Further analysis revealed
a deleterious missense mutation affecting the MutS
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domain III (T767I) of mutS homolog 6 (MSH6), a gene
involved in the DNA MMR mechanism, which was
shown to lead to hypermutated cancers [22, 23].
Based on the results supporting formation of DMs as
well as the hypermutated phenotype, a combination
therapy targeting both of the molecular events was de-
signed. The patient was started on hydroxyurea and an
immune checkpoint inhibitor, pembrolizumab, targeting
the PD-1 molecule, together with radiation therapy, po-
tentially helping to release the immune targets. Indeed,
A
B
Fig. 2 Genomic profile of the presented case. a Circos plot representing the CNV status of the original GBM and two recurrences. The innermost
circle represents the primary tumor, whereas the middle and outer-most circles depict the first and second recurrences, respectively (black, no
event; blue, deletion; red, amplification). b IGV plot of the locus of the EGFR A289V mutation in three tumors and matching blood. All three
tumors show amplification at the locus but only the primary tumor has supporting reads for variant A289V
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recent studies reported other hypermutated solid tu-
mors, including colorectal, endometrial, gastric, and
small bowel cancers, as well as cholangiocarcinoma, to
be potentially susceptible to immune checkpoint inhibi-
tors [24].
Remarkably, in March 2015, 5 months after the start
of the combination therapy of pembrolizumab and
hydroxurea in October 2014, an MRI revealed a decrease
in tumor size. The disease remained stable without
further progression until mid-June 2015, at which
time a repeat scan revealed increased perfusion, sug-
gesting progression with leptomeningeal spread. Hy-
droxyurea was stopped and bevacizumab was started
(Fig. 1). After being clinically stable for several months,
her neurological condition deteriorated and she died in
November 2015.
Given the potential clinical implications of these mo-
lecular findings, specifically the chromothripsis and
hypermutated phenotypes, we next interrogated the
Yale-Glioma cohort for similar events. This collection
contains 110 tumor-normal matched primary or sec-
ondary gliomas with WES data, 24 of which have also
been whole-genome sequenced. We found that 31%
of all primary GBMs (16/52) and only 1.7% (1/57) of
secondary GBMs had undergone chromothripsis (Fig. 4;
Additional file 2: Figure S1). Besides the frequently al-
tered, previously reported loci (chromosomes 7p11
and 12q13-15) [25], our analysis also revealed novel
loci on chromosomes 1p36 (harboring MTOR, n = 1),
1q32 (harboring MDM4, n = 2), 6q21 (harboring the
autophagy protein 5 gene, ATG5, n = 1) and 16q13
(harboring a cluster of metallothionein (MT) genes, n
= 1) to be amplified in GBM samples (Fig. 4a–d; Add-
itional file 2: Figures S2 and S3). Among these, ATG5
is responsible for autophagasome formation and, to
our knowledge, this is the first time ATG5 is reported
to have high copy number amplification due to chro-
mothripsis. We correlated the observed locus ploidy
with the available gene expression data to show that
the high ATG5 ploidy was concurrent with increased
gene expression, suggesting mechanistic significance
(Additional file 2: Figure S2). MT genes are known to
bind to physiological or xenobiotic heavy metals, such
as alkylating agents, used therapeutically, which leads
to resistance and treatment failures [26]. In addition,
we identified two samples with inter-chromosomal
breaks linking deleted segments; one secondary GBM
case between chromosomes 3p24-p13 and 5p13.2
(Fig. 4e) and another primary GBM case between
chromosomes 12p13 and 20q13.12-13 (Fig. 4f ). Fur-
ther studies are required to assess the frequency and
clinical significance of such events. We also checked
the Yale-Glioma cohort for any additional hypermu-
tated cases and identified a single patient (out of 52
primary GBMs, 1.9%) to have a MMR deficiency lead-
ing to a hypermutated phenotype. This tumor also
harbored a somatic, predicted deleterious missense
mutation located on the MutS domain II of MSH6
(C687Y).
We later performed a longitudinal analysis of our pa-
tient to assess the temporal evolution of the tumor and
potential impact of the acquired MMR deficiency. We
performed a model-based clustering analysis of the
clonality rates of the unique somatic mutations, in-
cluding both the coding and non-coding (captured)
ones in all three samples (Additional file 3). This
analysis revealed that while one major clone was pre-
served across all tumors (cluster 1), another clone
was lost (cluster 8, including EGFR A289V) and
many new sub-clones emerged in the second recur-
rence, consistent with the acquired MMR deficiency
(Fig. 5a). In addition, the second recurrence displayed
a distinct mutation signature, with a drastic increase
in the C > T transition ratio (97 versus 68 and 54%
in the second recurrence versus the primary tumor
and first recurrence, respectively), consistent with the
previously described findings after exposure to alkyl-
ating agents (Fig. 5b, c) [27–30].
Discussion
The longitudinal genomic profiling carried out in this
study demonstrates that the genomic profile of a
Fig. 3 FISH analysis for EGFR and MDM4. FISH analysis of the second
recurrence tumor displays the high ploidy states of EGFR (red) and
MDM4 (green). The smaller panel displays a control sample with two
copies of EGFR and MDM4
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tumor can evolve with treatments, leading to selection
of resistant sub-clones while eradicating others. Our
observations also emphasize the necessity of genomic
profiling and comparative analyses for each clinical re-
currence or progression. We demonstrate that intra-
tumoral heterogeneity in GBM is caused by temporal
evolution of the tumor as well as mechanisms leading
to large-scale genomic alterations, such as chromo-
thripsis, creating therapy-resistant clones. Moreover,
we report chromothripsis events leading to DMs to be
a frequent event in primary GBMs, especially when
compared to other cancer types. We also identified
novel loci being affected by chromothripsis by extend-
ing our study to the Yale-Glioma cohort, which might
have effects on the targeted treatments. Hence, the
presence of DMs, which would limit the therapeutic
success of targeted therapies, should be strongly con-
sidered when personalized glioma treatments are
planned, such as hydroxurea or gemcitabine [31, 32].
The new loci presented in this study to be affected
by chromothripsis should be further investigated to
access the functional and clinical significance. Finally,
Fig. 4 Cases with chromothripsis in the Yale-Glioma cohort. Circos plots of six GBM cases with chromothripsis (only affected chromosomes are
plotted). The outer-most circles depict the chromosomes (numbers shown) and shift in lesser allele frequency (in orange), respectively. The next
track plots the copy number status (black, no event; blue, deletion; red, amplification). Links in the inner track display the inter- or intra-chromosomal
breaks. a A GBM with chromothripsis affecting chromosome (chr) 12 and chr7 with high level amplification and a large number of inter-chromosomal
breaks. b Chr1–chr7 chromothripsis event with high level amplification. c Chr12–chr6 event with high level amplification and inter-chromosomal
breaks. d Chr7–chr16 chromothripsis with high level of amplification. e Chr3–chr5 event causing deletion in secondary GBM case. f Chr12–chr20
deletion with inter-chromosomal breaks
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we presented the potential positive response to check-
point inhibitors in gliomas, where the cases present
resistance to alkylating agent treatment due to ac-
quired MMR deficiency during progression. Further
studies will be needed to assess the exact extent of
the therapeutic impact of the immune checkpoint in-
hibitors in the treatment of gliomas with hypermu-
tated phenotypes.
Conclusions
Our study exemplifies how genomic profiling can suc-
cessfully guide personalized treatment regimens, even
in aggressive cancers such as GBM. Our study also
demonstrates that intra-tumoral heterogeneity, one of
the causes of therapy resistance in GBMs, does not
occur due just to the variation in somatic alterations
but also to mechanisms leading to large-scale genomic
alterations, such as chromothripsis. Moreover, our
study presents the checkpoint inhibitors as a new po-
tential targeted treatment agent in gliomas, especially
in cases with acquired MMR deficiency resulting in a
hypermutated phenotype and resistance to standard al-
kylating agent treatment.
Overall, with the presented case, we demonstrate the
importance of longitudinal genomic profiling to adjust
to the dynamic nature of treatment-induced molecular
changes to improve the outcomes of precision therapies.
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Additional file 1: Supplementary methods. (PDF 90 kb)
Additional file 2: Supplementary figures. Figure S1 Circos plots of
cases in the Yale-Glioma cohort that are identified to have gone
through chromothripsis. Figure S2 ATG5 gene amplification through
chromothripsis. Figure S3 Increased levels of MT group genes by a
Fig. 5 Clonal evolution and mutation signature analysis of the presented case. a Clonal evolution of the primary tumor, first recurrence and
second recurrence. Nine unique somatic mutation clusters are identified. Whereas cluster 1 contains the high clonal somatic mutations that are
preserved through the evolution of the tumor, cluster 8 represents mutations that are lost (or preserved with very low clonality) during
recurrence. Interestingly, all the remaining clusters contain mutations that are unique to the second recurrence tumor, with the exception of
mutations in cluster 6, which emerged during the first recurrence. b Mutational signatures of tumors reveal an increased burden of C to T
alteration for the second recurrence due to acquired MMR deficiency. All mutational signatures are shown with the color codes explained at the
bottom. c Distribution of somatic mutation signatures including the 5′ and 3′ flanking bases. The second recurrence has an increase in C > T
alterations in addition to the hypermutated phenotype and displays a signature similar to the one induced by the alkylating agents [33]
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focal amplification in a whole-genome genotyping experiment.
(PDF 465 kb)
Additional file 3: Supplementary table. Somatic mutations in three
tumors of the presented case. (XLSX 798 kb)
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